Resmed Aktie 1058638 / AU000000RMD6
22.91
USD
-1.05
USD
-4.36%
20.12.2024
NASO
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Resmed Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2024 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 1.02 | 0.30 | AUD |
| 2023 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 0.67 | 0.22 | AUD |
| 2022 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 0.54 | 0.17 | AUD |
| 2021 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 0.45 | 0.15 | AUD |
| 2020 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 0.65 | 0.18 | AUD |
| 2019 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 0.84 | 0.14 | AUD |
| 2018 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 0.90 | 0.13 | AUD |
| 2017 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 1.61 | 0.16 | AUD |
| 2016 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 1.47 | 0.12 | AUD |
| 2015 | Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | 1.57 | 0.11 | AUD |
Gewinn je Aktie- Resmed
| 1.1 24 | 0.9 23 | 0.7 22 | 0.4 21 | 0.6 20 | 0.4 19 | 0.3 18 |
Umsatz je Aktie- Resmed
| 4.8 24 | 4.3 23 | 3.4 22 | 2.9 21 | 3.0 20 | 2.5 19 | 2.1 18 |
KGV- Resmed
| 27.6 24 | 36.2 23 | 42.0 22 | 75.4 21 | 43.3 20 | 43.8 19 | 49.8 18 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh: Die Aktie (in AUD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 1.06 | 0.91 | 0.73 | 0.43 | 0.64 | 0.39 | 0.28 |
| Gewinn je Aktie unverwässert | 1.06 | 0.91 | 0.74 | 0.44 | 0.64 | 0.40 | 0.29 |
| Gewinn je Aktie verwässert | 1.06 | 0.91 | 0.73 | 0.43 | 0.64 | 0.39 | 0.28 |
| Dividende pro Aktie | 0.30 | 0.22 | 0.17 | 0.15 | 0.18 | 0.14 | 0.13 |
| Gesamtdividendenausschüttung in Mio. | 430.83 | 383.97 | 338.31 | 303.93 | 335.77 | 296.04 | 257.47 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh: Unternehmenskennzahlen (in AUD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 4.85 | 4.26 | 3.36 | 2.93 | 3.03 | 2.52 | 2.10 |
| KGV (Jahresendkurs, EPS unverwässert) | 27.56 | 36.24 | 41.99 | 75.41 | 43.25 | 43.85 | 49.84 |
| KGV (Jahresendkurs, EPS verwässert) | 27.56 | 36.26 | 41.99 | 75.41 | 43.25 | 43.85 | 49.84 |
| KGV (Jahresendkurs) | 27.56 | 36.24 | 41.99 | 75.41 | 43.25 | 43.85 | 49.84 |
| Dividendenrendite Jahresende in % | 1.02 | 0.67 | 0.54 | 0.45 | 0.65 | 0.84 | 0.90 |
| Eigenkapitalquote in % | 70.78 | 61.17 | 65.95 | 61.03 | 54.43 | 50.45 | 67.20 |
| Fremdkapitalquote in % | 29.22 | 38.83 | 34.05 | 38.97 | 45.57 | 49.55 | 32.80 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh: GuV (in Mio. AUD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 7’149.98 | 6’278.17 | 4’934.05 | 4’285.61 | 4’411.00 | 3’644.78 | 3’020.23 |
| Umsatzveränderung in % | 13.89 | 27.24 | 15.13 | -2.84 | 21.02 | 20.68 | 10.21 |
| Bruttoergebnis vom Umsatz | 3’981.12 | 3’439.61 | 2’748.56 | 2’423.80 | 2’517.55 | 2’043.83 | 1’698.13 |
| Bruttoergebnisveränderung in % | 15.74 | 25.14 | 13.40 | -3.72 | 23.18 | 20.36 | 10.86 |
| Operatives Ergebnis | 2’112.23 | 1’712.63 | 1’379.34 | 1’223.08 | 1’206.88 | 889.30 | 723.07 |
| Veränderung Operatives Ergebnis in % | 23.33 | 24.16 | 12.78 | 1.34 | 35.71 | 22.99 | 19.39 |
| Ergebnis vor Steuern | 1’930.14 | 1’637.80 | 1’324.46 | 1’184.62 | 1’093.55 | 725.51 | 672.80 |
| Veränderung Ergebnis vor Steuern in % | 17.85 | 23.66 | 11.80 | 8.33 | 50.73 | 7.83 | 21.17 |
| Ergebnis nach Steuer | 1’558.02 | 1’334.36 | 1’074.80 | 636.11 | 927.36 | 565.74 | 407.29 |
| Veränderung Ergebnis nach Steuer in % | 16.76 | 24.15 | 68.96 | -31.41 | 63.92 | 38.90 | -10.26 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh: Bilanz (in Mio. AUD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 3’007 | 3’939 | 2’523 | 2’454 | 3’036 | 2’901 | 1’360 |
| Langzeit Gesamtverbindlichk. pro Aktie | 1.12 | 1.90 | 1.04 | - | 1.49 | 1.47 | 0.47 |
| Eigenkapital | 7’283 | 6’204 | 4’887 | 3’844 | 3’627 | 2’953 | 2’787 |
| Veränderung Eigenkapital in % | 17.39 | 26.95 | 27.15 | 5.98 | 22.82 | 5.96 | 9.04 |
| Bilanzsumme | 10’290 | 10’143 | 7’411 | 6’298 | 6’663 | 5’853 | 4’147 |
| Veränderung Bilanzsumme in % | 1.45 | 36.87 | 17.67 | -5.48 | 13.83 | 41.15 | -8.29 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh: Sonstige Angaben (in AUD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 1.06 | 0.91 | 0.74 | 0.44 | 0.64 | 0.40 | 0.29 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 16.55 | 23.57 | 68.07 | -31.86 | 62.53 | 38.56 | -11.09 |
| Gewinn je Aktie (verwässert) | 1.06 | 0.91 | 0.73 | 0.43 | 0.64 | 0.39 | 0.28 |
| Veränderung Gewinn je Aktie (verwässert) in % | 16.69 | 23.81 | 68.26 | -31.77 | 62.59 | 38.42 | -11.09 |
| Anzahl Mitarbeiter | 9’980 | 10’140 | 8’160 | 7’970 | 7’770 | 7’240 | 5’940 |
| Veränderung Anzahl Mitarbeiter in % | -1.58 | 24.26 | 2.38 | 2.57 | 7.32 | 21.89 | -2.30 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | Quartalszahlen | 23.01.2025 |
| Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | Quartalszahlen | 24.04.2025 |
| Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | Quartalszahlen | 31.07.2025 |
| Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh | Quartalszahlen | 23.10.2025 |
Resmed Inc (CDI) on a ratio of 10 CDIs per ord.sh vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Hauptversammlung | Annual General Meeting | 21.11.2024 |
| Quartalszahlen | Q1 2025 Earnings Release | 24.10.2024 |
| Quartalszahlen | Q4 2024 Earnings Release | 01.08.2024 |
| Quartalszahlen | Q3 2024 Earnings Release | 25.04.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 24.01.2024 |
| Hauptversammlung | Annual General Meeting | 16.11.2023 |
| Quartalszahlen | Q1 2024 Earnings Release | 26.10.2023 |
| Quartalszahlen | Q4 2023 Earnings Release | 03.08.2023 |
| Quartalszahlen | Q3 2023 Earnings Release | 27.04.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 26.01.2023 |
| Hauptversammlung | Annual General Meeting | 17.11.2022 |
| Quartalszahlen | Q1 2023 Earnings Release | 27.10.2022 |
| Quartalszahlen | Q4 2022 Earnings Release | 11.08.2022 |
| Quartalszahlen | Q3 2022 Earnings Release | 28.04.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 27.01.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 100.00 |
| Vanguard Australian Shares Index Fund | 0.63 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 5’940 | 7’240 | 7’770 | 7’970 | 8’160 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.51 | 0.50 | 0.57 | 0.54 | 0.60 |
Bilanz (in Mio. AUD) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1’442 | 1’632 | 2’213 | 2’098 | 2’809 |
| Summe Anlagevermögen | 2’704 | 4’221 | 4’450 | 4’200 | 4’602 |
| Summe Aktiva | 4’147 | 5’853 | 6’663 | 6’298 | 7’411 |
Bilanz (in Mio. AUD) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 1’360 | 2’901 | 3’036 | 2’454 | 2’523 |
| Summe Eigenkapital | 2’787 | 2’953 | 3’627 | 3’844 | 4’887 |
| Summe Passiva | 4’147 | 5’853 | 6’663 | 6’298 | 7’411 |
Adresse
| 9001 Spectrum Center Boulevard, 92123 San Diego | |
| Telefon | +1 (858) 836-5000 |
| URL | http://www.resmed.com |
Management
|
Alastair Robertson
Chief Information Officer |
|
Amy Wakeham
Chief Investor Relations Officer |
|
Andrew Price
Chief Supply Chain Officer |
|
Bobby Ghoshal
Chief Commercial Officer-SaaS |
|
Brett A. Sandercock
Chief Financial Officer |
|
Carlos M. Nunez
Chief Medical Officer |
|
Carol J. Burt
Independent Director |
|
Christopher J. DelOrefice
Independent Director |
|
Dawn Haake
Chief Quality Officer |
|
Desney Tan
Independent Director |
|
Geoff Neilson
Senior Vice President-Global Supplier Alliance |
|
Harjit Gill
Independent Director |
|
Hemanth Reddy
Chief Strategy Officer |
|
Jan D. de Witte
Independent Director |
|
Jim Ellis
Chief Compliance Officer |
|
John B. Hernandez
Independent Director |
|
Justin G. Leong
Chief Product Officer |
|
Karen Ruth Drexler
Independent Director |
|
Lucile Blaise
Senior VP-Strategy & Business Development |
|
Michael Fliss
Chief Revenue Officer |
|
Michael J. Farrell
Chairman & Chief Executive Officer |
|
Michael Rider
Secretary & Chief Legal Officer |
|
Peter C. Farrell
Chairman-Emeritus |
|
Richard Sulpizio
Independent Director |
|
Ronald R. Taylor
Lead Independent Director |
|
Shane Azzi
Chief Supply Chain Officer |
|
Todd Friedman
Chief Information Security Officer |
|
Vered Keisar
Chief People Officer |
|
Yvonne-Katrin Pucknat
Chief Marketing Officer |